{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-241059","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.799056+00:00","generated_at":"2026-05-30T11:45:45.025733+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Artiva appoints Alison Moore Ph.D. as Class III director and committee member","bullets":["Alison Moore appointed as Class III director with term expiring at 2027 annual meeting; also joins Technical Operations Committee.","Dr. Moore is Chief Technical Officer at Codexis (since Oct 2024); previously CTO/EVP at Allogene Therapeutics and SVP at Amgen.","Receives annual cash retainer of $40,000 for board service and $15,000 for Technical Operations Committee service.","Granted option to purchase 27,500 shares, one-third vested immediately, remainder vesting monthly over two years.","Will receive automatic annual option grants of 13,750 shares at each annual meeting, vesting over one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-241059","json":"https://secwatch.observer/filing/0001193125-24-241059.json","markdown":"https://secwatch.observer/filing/0001193125-24-241059.md","text":"https://secwatch.observer/filing/0001193125-24-241059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312524241059/0001193125-24-241059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312524241059/d855080d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:45:45.025733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe99d37f49","claim":"Alison Moore was appointed as Class III Director at Artiva Biotherapeutics, Inc..","evidence_excerpt":"appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312524241059/0001193125-24-241059-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}